Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision Medicine in Lymphoma by Innovative Instrumental Platforms.
Di Paolo A, Arrigoni E, Luci G, Cucchiara F, Danesi R, Galimberti S. Di Paolo A, et al. Among authors: galimberti s. Front Oncol. 2019 Dec 17;9:1417. doi: 10.3389/fonc.2019.01417. eCollection 2019. Front Oncol. 2019. PMID: 31921674 Free PMC article. Review.
Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.
Galimberti S, Petrini M, Baratè C, Ricci F, Balducci S, Grassi S, Guerrini F, Ciabatti E, Mechelli S, Di Paolo A, Baldini C, Baglietto L, Macera L, Spezia PG, Maggi F. Galimberti S, et al. Front Oncol. 2020 Sep 2;10:1428. doi: 10.3389/fonc.2020.01428. eCollection 2020. Front Oncol. 2020. PMID: 33014780 Free PMC article.
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
Polillo M, Galimberti S, Baratè C, Petrini M, Danesi R, Di Paolo A. Polillo M, et al. Among authors: galimberti s. Int J Mol Sci. 2015 Sep 21;16(9):22811-29. doi: 10.3390/ijms160922811. Int J Mol Sci. 2015. PMID: 26402671 Free PMC article. Review.
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
Galeotti L, Ceccherini F, Domingo D, Laurino M, Polillo M, Di Paolo A, Baratè C, Fava C, D'Avolio A, Cervetti G, Guerrini F, Fontanelli G, Ciabatti E, Grassi S, Arrigoni E, Danesi R, Petrini M, Cornolti F, Saglio G, Galimberti S. Galeotti L, et al. Among authors: galimberti s. Cancer Chemother Pharmacol. 2017 Apr;79(4):767-773. doi: 10.1007/s00280-017-3271-3. Epub 2017 Mar 13. Cancer Chemother Pharmacol. 2017. PMID: 28289867
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia.
Galimberti S, Grassi S, Baratè C, Guerrini F, Ciabatti E, Perutelli F, Ricci F, Del Genio G, Montali M, Barachini S, Giuliani C, Ferreri MI, Valetto A, Abruzzese E, Ippolito C, Iurlo A, Bocchia M, Sicuranza A, Martino B, Iovino L, Buda G, Salehzadeh S, Petrini M, Di Paolo A, Mattii L. Galimberti S, et al. Front Oncol. 2018 Dec 6;8:555. doi: 10.3389/fonc.2018.00555. eCollection 2018. Front Oncol. 2018. PMID: 30574454 Free PMC article.
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia.
Grassi S, Palumbo S, Mariotti V, Liberati D, Guerrini F, Ciabatti E, Salehzadeh S, Baratè C, Balducci S, Ricci F, Buda G, Iovino L, Mazziotta F, Ghio F, Ercolano G, Di Paolo A, Cecchettini A, Baldini C, Mattii L, Pellegrini S, Petrini M, Galimberti S. Grassi S, et al. Among authors: galimberti s. Front Oncol. 2019 Jun 24;9:532. doi: 10.3389/fonc.2019.00532. eCollection 2019. Front Oncol. 2019. PMID: 31293972 Free PMC article.
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.
Loscocco F, Visani G, Ruzzo A, Bagaloni I, Fuligni F, Galimberti S, Di Paolo A, Stagno F, Pregno P, Annunziata M, Gozzini A, Barulli S, Gabucci E, Magnani M, Isidori A. Loscocco F, et al. Among authors: galimberti s. Front Oncol. 2021 May 13;11:672287. doi: 10.3389/fonc.2021.672287. eCollection 2021. Front Oncol. 2021. PMID: 34055641 Free PMC article.
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.
Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. Galimberti S, et al. Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152138 Free PMC article.
446 results